Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Chronic Heart Failure

Free Subscription Articles published in Cardiovasc Res Retrieve available abstracts of 84 articles: HTML format

Single Articles

March 2023
1. MARKOUSIS-MAVROGENIS G, Minich WB, Al-Mubarak AA, Anker SD, et al
   Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure.
   Cardiovasc Res. 2023 Mar 8:cvad042. doi: 10.1093.
   PubMed     Abstract available
   
   
   February 2023
2. 
   Corrigendum to: Global burden of heart failure: a comprehensive and updated review of epidemiology.
   Cardiovasc Res. 2023 Feb 9:cvad026. doi: 10.1093.
   PubMed    
   
   
   
3. CAPONE F, Sotomayor-Flores C, Bode D, Wang R, et al
   Cardiac metabolism in HFpEF: from fuel to signalling.
   Cardiovasc Res. 2023;118:3556-3575.
   PubMed     Abstract available
   
   
   
4. PORCARI A, Fontana M, Gillmore JD
   Transthyretin cardiac amyloidosis.
   Cardiovasc Res. 2023;118:3517-3535.
   PubMed     Abstract available
   
   
   
5. DULCE RA, Kanashiro-Takeuchi RM, Takeuchi LM, Salerno AG, et al
   Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of heart failure with preserved ejection fraction.
   Cardiovasc Res. 2023;118:3586-3601.
   PubMed     Abstract available
   
   
   January 2023
6. 
   Erratum to: Phenomapping in heart failure with preserved ejection fraction: insights, limitations, and future directions.
   Cardiovasc Res. 2023 Jan 21:cvad002. doi: 10.1093.
   PubMed    
   
   
   
7. RAGNI M, Greco CM, Felicetta A, Ren SV, et al
   Dietary essential amino acids for the treatment of heart failure with reduced ejection fraction.
   Cardiovasc Res. 2023 Jan 10:cvad005. doi: 10.1093.
   PubMed     Abstract available
   
   
   December 2022
8. THUM T, Lam CSP
   Accelerating developments in heart failure.
   Cardiovasc Res. 2022 Dec 30:cvac185. doi: 10.1093.
   PubMed    
   
   
   
9. VANHAVERBEKE M, Attard R, Bartekova M, Ben-Aicha S, et al
   Peripheral blood RNA biomarkers for cardiovascular disease from bench to bedside: a position paper from the EU-CardioRNA COST action CA17129.
   Cardiovasc Res. 2022;118:3183-3197.
   PubMed     Abstract available
   
   
   
10. KHAN MS, Shahid I, Greene SJ, Mentz RJ, et al
    Mechanisms of current therapeutic strategies for heart failure: more questions than answers?
    Cardiovasc Res. 2022 Dec 20:cvac187. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. HUNKLER HJ, Gross S, Thum T, Bar C, et al
    Non-coding RNAs: key regulators of reprogramming, pluripotency, and cardiac cell specification with therapeutic perspective for heart regeneration.
    Cardiovasc Res. 2022;118:3071-3084.
    PubMed     Abstract available
    
    
    November 2022
12. PETERS AE, Tromp J, Shah SJ, Lam CSP, et al
    Phenomapping in heart failure with preserved ejection fraction - insights, limitations, and future directions.
    Cardiovasc Res. 2022 Nov 30:cvac179. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. LOESCHER CM, Hobbach AJ, Linke WA
    Titin (TTN): from molecule to modifications, mechanics, and medical significance.
    Cardiovasc Res. 2022;118:2903-2918.
    PubMed     Abstract available
    
    
    September 2022
14. VIDEIRA RF, Koop AMC, Ottaviani L, Poels EM, et al
    The adult heart requires baseline expression of the transcription factor Hand2 to withstand right ventricular pressure overload.
    Cardiovasc Res. 2022;118:2688-2702.
    PubMed     Abstract available
    
    
    
15. 
    Corrigendum to: Temporal relationship between systemic endothelial dysfunction and alterations in erythrocyte function in a murine model of chronic heart failure.
    Cardiovasc Res. 2022 Sep 15. pii: 6698740. doi: 10.1093.
    PubMed    
    
    
    August 2022
16. MCKINSEY TA, Foo R, Anene-Nzelu CG, Travers JG, et al
    Emerging epigenetic therapies of cardiac fibrosis and remodeling in heart failure: from basic mechanisms to early clinical development.
    Cardiovasc Res. 2022 Aug 25. pii: 6675295. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. PUGLIESE NR, Pellicori P, Filidei F, De Biase N, et al
    Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions.
    Cardiovasc Res. 2022 Aug 25. pii: 6675297. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. JESON SANGARALINGHAM S, Kuhn M, Cannone V, Chen HH, et al
    Natriuretic peptide pathways in heart failure - further therapeutic possibilities.
    Cardiovasc Res. 2022 Aug 25. pii: 6675294. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. DE WIT S, Glen C, de Boer RA, Lang NN, et al
    Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies.
    Cardiovasc Res. 2022 Aug 25. pii: 6675097. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. THIELE A, Luettges K, Ritter D, Beyhoff N, et al
    Pharmacological inhibition of adipose tissue adipose triglyceride lipase by Atglistatin prevents catecholamine-induced myocardial damage.
    Cardiovasc Res. 2022;118:2488-2505.
    PubMed     Abstract available
    
    
    July 2022
21. SAVARESE G, Butler J, Lund LH, Bhatt DL, et al
    Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms.
    Cardiovasc Res. 2022;118:2231-2252.
    PubMed     Abstract available
    
    
    
22. BORLAUG BA, Jensen MD, Kitzman DW, Lam CSP, et al
    Obesity and heart failure with preserved ejection fraction: new insights and pathophysiologic targets.
    Cardiovasc Res. 2022 Jul 26. pii: 6649894. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. JANG AY, Scherer PE, Kim JY, Lim S, et al
    Adiponectin and cardiometabolic trait and mortality: where do we go?
    Cardiovasc Res. 2022;118:2074-2084.
    PubMed     Abstract available
    
    
    
24. SASSET L, Manzo OL, Zhang Y, Marino A, et al
    Nogo-A reduces ceramide de novo biosynthesis to protect from heart failure.
    Cardiovasc Res. 2022 Jul 11. pii: 6639610. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. KEEFE J, Wehrens XH, Dobrev D
    Common disease-promoting signaling pathways in heart failure and atrial fibrillation: putative underlying mechanisms and potential therapeutic consequences.
    Cardiovasc Res. 2022 Jul 5. pii: 6631397. doi: 10.1093.
    PubMed    
    
    
    June 2022
26. LUSCHER TF, Akhtar MM
    Looking deeper into takotsubo's heart.
    Cardiovasc Res. 2022;118:1851-1853.
    PubMed    
    
    
    
27. PORTERO V, Nicol T, Podliesna S, Marchal GA, et al
    Chronically elevated branched chain amino acid levels are pro-arrhythmic.
    Cardiovasc Res. 2022;118:1742-1757.
    PubMed     Abstract available
    
    
    
28. JACKSON MR, Cox KD, Baugh SDP, Wakeen L, et al
    Discovery of a first-in-class inhibitor of sulfide:quinone oxidoreductase that protects against adverse cardiac remodelling and heart failure.
    Cardiovasc Res. 2022;118:1771-1784.
    PubMed     Abstract available
    
    
    
29. KUMARI R, Ranjan P, Suleiman ZG, Goswami SK, et al
    mRNA modifications in cardiovascular biology and disease: with a focus on m6A modification.
    Cardiovasc Res. 2022;118:1680-1692.
    PubMed     Abstract available
    
    
    
30. DHINGRA R, Kirshenbaum LA
    ULK1 mediated mitophagy prevents pathological cardiac remodelling and heart failure.
    Cardiovasc Res. 2022 Jun 21. pii: 6612712. doi: 10.1093.
    PubMed     Abstract available
    
    
    
31. HERON C, Dumesnil A, Houssari M, Renet S, et al
    Regulation and impact of cardiac lymphangiogenesis in pressure-overload-induced heart failure.
    Cardiovasc Res. 2022 Jun 11. pii: 6605782. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2022
32. ROUHI L, Fan S, Cheedipudi SM, Braza-Boils A, et al
    The EP300/TP53 pathway, a suppressor of the Hippo and canonical WNT pathways, is activated in human hearts with arrhythmogenic cardiomyopathy in the absence of overt heart failure.
    Cardiovasc Res. 2022;118:1466-1478.
    PubMed     Abstract available
    
    
    April 2022
33. TUAL-CHALOT S, Stellos K
    Targeting the adipose tissue: heart crosstalk in pressure overload-induced heart failure.
    Cardiovasc Res. 2022 Apr 13. pii: 6568065. doi: 10.1093.
    PubMed    
    
    
    
34. 
    Corrigendum to: Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF.
    Cardiovasc Res. 2022 Apr 9. pii: 6565889. doi: 10.1093.
    PubMed    
    
    
    March 2022
35. YU JK, Liang JA, Franceschi WH, Huang Q, et al
    Assessment of arrhythmia mechanism and burden of the infarcted ventricles following remuscularization with pluripotent stem cell-derived cardiomyocyte patches using patient-derived models.
    Cardiovasc Res. 2022;118:1247-1261.
    PubMed     Abstract available
    
    
    
36. GATICA D, Chiong M, Lavandero S, Klionsky DJ, et al
    The role of autophagy in cardiovascular pathology.
    Cardiovasc Res. 2022;118:934-950.
    PubMed     Abstract available
    
    
    
37. MURPHY KA, Harsch BA, Healy CL, Joshi SS, et al
    Free fatty acid receptor 4 responds to endogenous fatty acids to protect the heart from pressure overload.
    Cardiovasc Res. 2022;118:1061-1073.
    PubMed     Abstract available
    
    
    February 2022
38. PITOULIS FG, Nunez-Toldra R, Xiao K, Kit-Anan W, et al
    Remodelling of adult cardiac tissue subjected to physiological and pathological mechanical load in vitro.
    Cardiovasc Res. 2022;118:814-827.
    PubMed     Abstract available
    
    
    
39. SAVARESE G, Becher PM, Lund LH, Seferovic P, et al
    Global burden of heart failure: A comprehensive and updated review of epidemiology.
    Cardiovasc Res. 2022 Feb 12. pii: 6527627. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2022
40. BERTERO E, Dudek J, Cochain C, Delgobo M, et al
    Immuno-metabolic interfaces in cardiac disease and failure.
    Cardiovasc Res. 2022;118:37-52.
    PubMed     Abstract available
    
    
    December 2021
41. BENN M, Marott SCW, Tybjaerg-Hansen A, Nordestgaard BG, et al
    Obesity increases heart failure incidence and mortality: observational and Mendelian randomisation studies totalling over 1 million individuals.
    Cardiovasc Res. 2021 Dec 25. pii: 6483090. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. KARWI QG, Ho KL, Pherwani S, Ketema EB, et al
    Corrigendum to: Concurrent diabetes and heart failure: interplay and novel therapeutic approaches.
    Cardiovasc Res. 2021 Dec 13. pii: 6460360. doi: 10.1093.
    PubMed    
    
    
    October 2021
43. SANTEMA BT, Arita VA, Sama IE, Kloosterman M, et al
    Pathophysiological pathways in patients with heart failure and atrial fibrillation.
    Cardiovasc Res. 2021 Oct 23. pii: 6409189. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. MOHAISSEN T, Proniewski B, Targosz-Korecka M, Bar A, et al
    Temporal relationship between systemic endothelial dysfunction and alterations in erythrocyte function in a murine model of chronic heart failure.
    Cardiovasc Res. 2021 Oct 7. pii: 6383136. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2021
45. DAVIDSON SM, Padro T, Bollini S, Vilahur G, et al
    Progress in cardiac research: from rebooting cardiac regeneration to a complete cell atlas of the heart.
    Cardiovasc Res. 2021;117:2161-2174.
    PubMed     Abstract available
    
    
    
46. CAMPBELL H, Aguilar-Sanchez Y, Quick AP, Dobrev D, et al
    SPEG: a key regulator of cardiac calcium homeostasis.
    Cardiovasc Res. 2021;117:2175-2185.
    PubMed     Abstract available
    
    
    
47. FERREIRA JP, Ouwerkerk W, Santema BT, van Veldhuisen DJ, et al
    Differences in biomarkers and molecular pathways according to age for patients with HFrEF.
    Cardiovasc Res. 2021;117:2228-2236.
    PubMed     Abstract available
    
    
    
48. RICHARDS AM
    Proteomic probing for markers and mechanisms in Heart Failure.
    Cardiovasc Res. 2021 Aug 10. pii: 6347578. doi: 10.1093.
    PubMed    
    
    
    July 2021
49. ZHAO B, Bouchareb R, Lebeche D
    Resistin deletion protects against heart failure injury by targeting DNA damage response.
    Cardiovasc Res. 2021 Jul 29. pii: 6330773. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. ABDELLATIF M, Lam CSP
    Scientists on the Spot: A fraction of wisdom on heart failure.
    Cardiovasc Res. 2021;117:e114-e115.
    PubMed    
    
    
    
51. VOLPE M, Gallo G
    Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists.
    Cardiovasc Res. 2021;117:1992-1994.
    PubMed    
    
    
    
52. MARKOUSIS-MAVROGENIS G, Tromp J, Ouwerkerk W, Fereirra JP, et al
    Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF.
    Cardiovasc Res. 2021 Jul 15. pii: 6321950. doi: 10.1093.
    PubMed     Abstract available
    
    
    
53. DIEZ J, de Boer RA
    Management of cardiac fibrosis is the largest unmet medical need in heart failure Cardiac fibrosis in heart failure.
    Cardiovasc Res. 2021 Jul 9. pii: 6318397. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. GRASSI G, Mancia G, Esler M
    CENTRAL AND PERIPHERAL SYMPATHETIC ACTIVATION IN HEART FAILURE.
    Cardiovasc Res. 2021 Jul 7. pii: 6317668. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2021
55. ONODI Z, Ruppert M, Kucsera D, Sayour AA, et al
    AIM2-driven inflammasome activation in heart failure.
    Cardiovasc Res. 2021 Jun 12. pii: 6297397. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. SANSONETTI M, De Windt LJ
    Non-coding RNAs in cardiac inflammation: key drivers in the pathophysiology of heart failure.
    Cardiovasc Res. 2021 Jun 7. pii: 6294284. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. NAUMENKO N, Mutikainen M, Holappa L, Ruas JL, et al
    PGC-1alpha deficiency reveals sex-specific links between cardiac energy metabolism and EC-coupling during development of heart failure in mice.
    Cardiovasc Res. 2021 Jun 4. pii: 6292089. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2021
58. TAO Z, Loo S, Su L, Tan S, et al
    Angiopoietin-1 enhanced myocyte mitosis, engraftment, and the reparability of hiPSC-CMs for treatment of myocardial infarction.
    Cardiovasc Res. 2021;117:1578-1591.
    PubMed     Abstract available
    
    
    
59. 
    Corrigendum to: Heart failure or heart success?
    Cardiovasc Res. 2021 May 18. pii: 6277376. doi: 10.1093.
    PubMed    
    
    
    April 2021
60. MONMA Y, Shindo T, Eguchi K, Kurosawa R, et al
    Low-intensity pulsed ultrasound ameliorates cardiac diastolic dysfunction in mice: a possible novel therapy for heart failure with preserved left ventricular ejection fraction.
    Cardiovasc Res. 2021;117:1325-1338.
    PubMed     Abstract available
    
    
    
61. 
    Retraction: Influence of p53 in the transition of myotrophin-induced cardiac hypertrophy to heart failure.
    Cardiovasc Res. 2021 Apr 22. pii: 6245632. doi: 10.1093.
    PubMed    
    
    
    
62. BOLLI R, Solankhi M, Tang XL, Kahlon A, et al
    Cell Therapy in Patients with Heart Failure: A Comprehensive Review and Emerging Concepts.
    Cardiovasc Res. 2021 Apr 19. pii: 6237881. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2021
63. KARWI QG, Ho KL, Pherwani S, Ketema EB, et al
    Concurrent diabetes and heart failure: interplay and novel therapeutic approaches.
    Cardiovasc Res. 2021 Mar 30. pii: 6203809. doi: 10.1093.
    PubMed     Abstract available
    
    
    
64. SELVARAJ S, Margulies KB
    Exogenous ketones in the healthy heart: the plot thickens.
    Cardiovasc Res. 2021;117:995-996.
    PubMed    
    
    
    
65. BAUERSACHS J
    SCORED and SOLOIST: the next scores for SGLT2 inhibitors.
    Cardiovasc Res. 2021;117:e49-e51.
    PubMed    
    
    
    
66. ABE I, Terabayashi T, Hanada K, Kondo H, et al
    Disruption of actin dynamics regulated by Rho effector mDia1 attenuates pressure overload-induced cardiac hypertrophic responses and exacerbates dysfunction.
    Cardiovasc Res. 2021;117:1103-1117.
    PubMed     Abstract available
    
    
    
67. TAKAHARA S, Soni S, Maayah ZH, Ferdaoussi M, et al
    Ketone Therapy for Heart Failure: Current Evidence for Clinical Use.
    Cardiovasc Res. 2021 Mar 10. pii: 6168424. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. CUOMO A, Pirozzi F, Tocchetti CG
    Low-intensity pulsed ultrasound (LIPUS) in heart failure with preserved ejection fraction (HFpEF): lupus in fabula?
    Cardiovasc Res. 2021 Mar 5. pii: 6159769. doi: 10.1093.
    PubMed    
    
    
    February 2021
69. LUXAN G, Dimmeler S
    The vasculature: a therapeutic target in heart failure?
    Cardiovasc Res. 2021 Feb 23. pii: 6146925. doi: 10.1093.
    PubMed     Abstract available
    
    
    
70. TERAMOTO K, Tromp J, Lam CSP
    Heart failure or heart success?
    Cardiovasc Res. 2021 Feb 13. pii: 6134544. doi: 10.1093.
    PubMed    
    
    
    
71. DE LUCIA C, Grisanti LA, Borghetti G, Piedepalumbo M, et al
    GRK5 contributes to impaired cardiac function and immune cell recruitment in post-ischemic heart failure.
    Cardiovasc Res. 2021 Feb 9. pii: 6131786. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2021
72. HEGYI B, Ko CY, Bossuyt J, Bers DM, et al
    Two-hit mechanism of cardiac arrhythmias in diabetic hyperglycemia: reduced repolarization reserve, neurohormonal stimulation and heart failure exacerbate susceptibility.
    Cardiovasc Res. 2021 Jan 23. pii: 6105172. doi: 10.1093.
    PubMed     Abstract available
    
    
    
73. CICCARELLI M, Dawson D, Falcao-Pires I, Giacca M, et al
    Reciprocal organ interactions during heart failure-a position paper from the ESC working group on myocardial function.
    Cardiovasc Res. 2021 Jan 22. pii: 6105178. doi: 10.1093.
    PubMed     Abstract available
    
    
    
74. TOENNIS T, Kirchhof P
    Connecting the dots? Rate control, heart failure, and atrial fibrillation.
    Cardiovasc Res. 2021;117:336-337.
    PubMed    
    
    
    
75. PANENI F, Sciarretta S, Costantino S
    Tackling myocardial oxidative stress with empagliflozin: are we big enough to fight heart failure with preserved ejection fraction?
    Cardiovasc Res. 2021;117:343-345.
    PubMed    
    
    
    
76. GUICHARD JB, Xiong F, Qi XY, L'Heureux N, et al
    Role of atrial arrhythmia and ventricular response in atrial fibrillation induced atrial remodelling.
    Cardiovasc Res. 2021;117:462-471.
    PubMed     Abstract available
    
    
    
77. LIMA CORREA B, El Harane N, Gomez I, Rachid Hocine H, et al
    Extracellular vesicles from human cardiovascular progenitors trigger a reparative immune response in infarcted hearts.
    Cardiovasc Res. 2021;117:292-307.
    PubMed     Abstract available
    
    
    November 2020
78. MELI AC, Fischmeister R
    Scientists on the spot: Phosphodiesterases and heart failure.
    Cardiovasc Res. 2020 Nov 1. pii: 5952729. doi: 10.1093.
    PubMed    
    
    
    October 2020
79. NAKAMURA M, Odanovic N, Nakada Y, Dohi S, et al
    Dietary Carbohydrates Restriction Inhibits The Development Of Cardiac Hypertrophy And Heart Failure.
    Cardiovasc Res. 2020 Oct 18. pii: 5929700. doi: 10.1093.
    PubMed     Abstract available
    
    
    
80. PANICO C, Kallikourdis M, Condorelli G
    Defining circulating mononuclear cells in heart failure through single-cell RNA sequencing: new insights for an old disease.
    Cardiovasc Res. 2020 Oct 13. pii: 5922371. doi: 10.1093.
    PubMed    
    
    
    
81. LANG NN, Dobbin SJH, Petrie MC
    Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial.
    Cardiovasc Res. 2020;116:e152-e155.
    PubMed    
    
    
    July 2020
82. MELI AC, de Tombe P
    Scientists on the Spot: Myocardium and myofilaments.
    Cardiovasc Res. 2020;116:e96-e97.
    PubMed    
    
    
    March 2020
83. VAN BERLO JH, Garry DJ
    Hearts and Hands: the good, the bad, and the ugly.
    Cardiovasc Res. 2020;116:470-472.
    PubMed    
    
    
    
84. VOLLAND C, Schott P, Didie M, Manner J, et al
    Control of p21Cip by BRCA1-associated protein is critical for cardiomyocyte cell cycle progression and survival.
    Cardiovasc Res. 2020;116:592-604.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: